Transave

Monmouth Junction, United States Founded: 1997 • Age: 29 yrs Acquired By Insmed
Developer of inhaled pharmaceuticals for the site-specific treatment of serious lung infections
Annual revenue - Latest available
Total funding $13.0M 3 rounds
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 9 Brand Intelligence

About Transave

Transave is a company based in Monmouth Junction (United States) founded in 1997 was acquired by Insmed in December 2010. Transave has raised $13.04 million across 3 funding rounds from investors including Insmed. Transave operates in a competitive market with competitors including MannKind Corp, aTyr Pharma, ReCode Therapeutics, Impel NeuroPharma and Sirnaomics, among others.

  • Headquarter Monmouth Junction, United States
  • Sectors
    Technology
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Transave Inc
Operational Areas
Technology → Quantum & Emerging Technologies Unlock Sub-Sector Unlock Segment
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $13.04 M (USD)

    in 3 rounds

  • Latest Funding Round
    $2 M (USD), Series A

    Sep 28, 2010

  • Investors
  • Employee Count
    Not available
  • Acquired by
    Insmed

    (Dec 02, 2010)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Transave

Transave has successfully raised a total of $13.04M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $2 million completed in September 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Transave

Transave has secured backing from 1 investor. Prominent investors backing the company include Insmed.

All
Investor Description Founded Year Domain Location
Developer of small molecule inhibitors for rare lung diseases
Locked Locked Locked
Premium access

Investor details for Transave

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Transave

Investments
Premium access

Investment portfolio details for Transave

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Transave

Premium access

Detailed financials for Transave

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Transave Comparisons

Transave Primary company
Description
Developer of inhaled pharmaceuticals for the site-specific t...
Location
Monmouth Junction, United States
Founded Year
1997
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Transave

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Transave

Transave operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MannKind Corp, aTyr Pharma, ReCode Therapeutics, Impel NeuroPharma and Sirnaomics, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Developer of small-molecule drugs
Locked Locked Locked
Protein biologics are developed for treating rare diseases.
Locked Locked Locked
Precision medicines for lung-related diseases are developed.
Locked Locked Locked
Intranasal delivery technology for CNS diseases is developed.
Locked Locked Locked
RNA-based therapeutics for cancer and fibrosis are developed.
Locked Locked Locked
Developer of products for the treatment of acute and intermittent conditions
Premium access

Detailed competitors of Transave

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Transave

Premium access

Complete news archive for Transave

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Transave

Transave was founded in 1997 and raised its 1st funding round 12 years after it was founded.

Transave is headquartered in Monmouth Junction, United States. It is registered at Monmouth Junction, New Jersey, United States.

Transave is a funded company, having raised a total of $13.04M across 3 funding rounds to date.

Transave was founded in 1997 in Monmouth Junction, United States, within the biotechnology sector. Inhaled pharmaceuticals are developed by the company for targeted treatment of serious lung infections. The lead product, ARIKACE (liposomal amikacin for inhalation), is being advanced for cystic fibrosis patients facing Pseudomonas infections and those due to non-tuberculous Mycobacteria. Operations focus on respiratory therapeutics, with development centered in the U.S.

Transave's top competitors include MannKind Corp, Sirnaomics and Arcturus Therapeutics.

Transave has 1 investor. Key investors include Insmed.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available